Host: Mario R. Nacinovich, Jr., MSc

Guest: Sara Tolaney MD, MPH

Triple-negative breast cancer comprises up to 20 percent of all breast cancer diagnoses, and unfortunately, survival for these patients has been more limited than in other subtypes of disease. That’s why improving outcomes for patients with triple-negative breast cancer has been the focus of recent studies—much like the one investigating eribulin and pembrolizumab that Dr. Sara Tolaney, breast medical oncologist at the Dana-Farber Cancer Institute, presented at the 2020 ASCO Annual Meeting.